Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Generic Celecoxib vs CELEBREX in Healthy Thai Volunteers
NCT06337422Phase 1Not yet recruiting
- Sponsor
- International Bio Service
- Start
- Sep 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of celecoxib oral solution in osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis (AS) and 2 more (2 arms), sponsored by International Bio Service. Primary endpoints: Maximum Plasma Concentration at 72 hours and Area Under the Curve at 72 hours. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
celecoxib oral solution
03
Conditions
osteoarthritis (OA)rheumatoid arthritis (RA)ankylosing spondylitis (AS)acute painprimary dysmenorrhea (PD)
Beyond the preview
Go deeper on NCT06337422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06337422.